ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma - Episode 4

Recent Subgroup Analyses from the CLEAR study in Advanced RCC

, , , ,

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: First-Line Treatments for Advanced Clear Cell RCC
    EP. 2: Long-Term Follow-Up from CheckMate 214 in Advanced RCC
    EP. 3: CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC
    Now Viewing
    EP. 4: Recent Subgroup Analyses from the CLEAR study in Advanced RCC
    EP. 5: LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis
    EP. 6: Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC
    EP. 7: CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC
    EP. 8: Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC
    EP. 9: LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research
    EP. 10: Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC
    EP. 11: CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC
    EP. 12: Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC
    EP. 13: Clinical Insights on Belzutifan in Advanced RCC
    EP. 14: Overview of Non–Clear Cell RCC
    EP. 15: TKI Monotherapy Data in Non–Clear Cell RCC
    EP. 16: KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC
    EP. 17: Nivolumab Plus Cabozantinib in Non–Clear Cell RCC
    EP. 18: Future Perspectives and Unmet Needs in Renal Cell Carcinoma
    x